Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer:: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93

被引：10

作者：

Colleoni, Marco ^{[1
]}

Gelber, Shari ^{[1
]}

Simoncini, Edda ^{[1
]}

Pagani, Olivia ^{[1
]}

Gelber, Richard D. ^{[1
]}

Price, Karen N. ^{[1
]}

Castiglione-Gertsch, Monica ^{[1
]}

Coates, Alan S. ^{[1
]}

Goldhirsch, Aron ^{[1
]}

Goldhirsch, A. ^{[1
]}

Coates, A. S. ^{[1
]}

Thuerlimann, B. ^{[1
]}

Castiglione, M. ^{[1
]}

Coates, A. S. ^{[1
]}

Collins, J. P. ^{[1
]}

Funes, H. Cortes ^{[1
]}

Gelber, R. D. ^{[1
]}

Goldhirsch, A. ^{[1
]}

Green, M. ^{[1
]}

Hiltbrunner, A. ^{[1
]}

Holmberg, S. B. ^{[1
]}

Hossfeld, D. K. ^{[1
]}

Lang, I. ^{[1
]}

Lindtner, J. ^{[1
]}

Paganetti, F. ^{[1
]}

Rudenstam, C.-M. ^{[1
]}

Stahel, R. ^{[1
]}

Senn, H.-J. ^{[1
]}

Veronesi, A. ^{[1
]}

Castiglione-Gertsch, M. ^{[1
]}

Hiltbrunner, A. ^{[1
]}

Egli, G. ^{[1
]}

Rabaglio, M. ^{[1
]}

Studer, R. ^{[1
]}

Ruepp, B. ^{[1
]}

Maibach, R. ^{[1
]}

Marbot, E. ^{[1
]}

Strausak, M. ^{[1
]}

Gelber, R. ^{[1
]}

Price, K. ^{[1
]}

Gelber, S. ^{[1
]}

Cole, B. ^{[1
]}

Regan, M. ^{[1
]}

Zahrieh, D. ^{[1
]}

Sun, Z. ^{[1
]}

Bernhard, J. ^{[1
]}

Egli, G. ^{[1
]}

Huerny, Ch. ^{[1
]}

Blacher, L. ^{[1
]}

Celano, J. ^{[1
]}

机构：

[1] European Inst Oncol, Div Med Oncol, I-20141 Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷 / 07期

基金：

英国医学研究理事会;

关键词：

adjuvant therapy; chemotherapy; early-stage breast cancer; estrogen receptor; hormonal therapy; lymph node positive;

D O I：

10.1093/annonc/mdm091

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome. Patients and methods: From 1993 to 1999, IBCSG Trials 13-93 and 14-93 enrolled 2215 premenopausal and postmenopausal women with axillary node-positive, operable breast cancer. All patients received cyclophosphamide (Cytoxan, C) plus either doxorubicin (Adriamycin, A) or epirubicin (E) for four courses followed immediately (No Gap) or after a 16-week delay (Gap) by classical cyclophosphamide, methotrexate, and fluorouracil (CMF) for three courses. The median follow-up was 7.7 years. Results: The Gap and No-Gap groups had similar disease-free survival (DFS) and overall survival (OS). No identified subgroup showed a statistically significant difference, but exploratory subgroup analysis noted a trend towards decreased DFS for Gap compared with No Gap for women with estrogen receptor (ER)-negative tumors not receiving tamoxifen, especially evident during the first 2 years. Conclusions: A 16-week gap between adjuvant AC/EC and CMF provided no benefit and may have increased early recurrence rates in patients with ER-negative tumors.

引用

页码：1177 / 1184

页数：8

共 26 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2] Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer [J].

Anderson, William F. ;

Chen, Bingshu E. ;

Jatoi, Ismail ;

Rosenberg, Philip S. .

BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (01) :121-126

[3] Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J].

Berry, DA ;

Cirrincione, C ;

Henderson, IC ;

Citron, ML ;

Budman, DR ;

Goldstein, LJ ;

Martino, S ;

Perez, EA ;

Muss, HB ;

Norton, L ;

Hudis, C ;

Winer, EP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1658-1667

[4] Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors [J].

Colleoni, M ;

Bonetti, M ;

Coates, AS ;

Castiglione-Gertsch, M ;

Gelber, RD ;

Price, K ;

Rudenstam, CM ;

Lindtner, J ;

Collins, J ;

Thürlimann, B ;

Holmberg, S ;

Veronesi, A ;

Marini, G ;

Goldhirsch, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :584-590

[5] Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer [J].

Colleoni, M ;

Price, K ;

Castiglione-Gertsch, M ;

Goldhirsch, A ;

Coates, A ;

Lindtner, J ;

Collins, J ;

Gelber, RD ;

Thürlimann, B ;

Rudenstam, CM .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) :1693-1700

[6] Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index [J].

Colleoni, M ;

Li, SG ;

Gelber, RD ;

Price, KN ;

Coates, AS ;

Castiglione-Gertsch, M ;

Goldhirsch, A .

LANCET, 2005, 366 (9491) :1108-1110

[7] Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment [J].

Colleoni, M ;

Viale, G ;

Zahrieh, D ;

Pruneri, G ;

Gentilini, O ;

Veronesi, P ;

Gelber, RD ;

Curigliano, G ;

Torrisi, R ;

Luini, A ;

Intra, M ;

Galimberti, V ;

Renne, G ;

Nolè, F ;

Peruzzotti, G ;

Goldhirsch, A .

CLINICAL CANCER RESEARCH, 2004, 10 (19) :6622-6628

[8] Duration of adjuvant chemotherapy for breast cancer:: a joint analysis of two randomised trials investigating three versus six courses of CMF [J].

Colleoni, M ;

Litman, HJ ;

Castiglione-Gertsch, M ;

Sauerbrei, W ;

Gelber, RD ;

Bonetti, M ;

Coates, AS ;

Schumacher, M ;

Bastert, G ;

Rudenstam, CM ;

Schmoor, C ;

Lindtner, J ;

Collins, J ;

Thürlimann, B ;

Holmberg, SB ;

Crivellari, D ;

Beyerle, C ;

Neumann, RLA ;

Goldhirsch, A .

BRITISH JOURNAL OF CANCER, 2002, 86 (11) :1705-1714

[9]

COX DR, 1972, J R STAT SOC B, V34, P187

[10]

Elston C W, 2002, Histopathology, V41, P151

← 1 2 3 →